51
|
Cigarrán S, Pousa M, Castro MJ, González B, Martínez A, Barril G, Aguilera A, Coronel F, Stenvinkel P, Carrero JJ. Endogenous testosterone, muscle strength, and fat-free mass in men with chronic kidney disease. J Ren Nutr 2012; 23:e89-95. [PMID: 23046736 DOI: 10.1053/j.jrn.2012.08.007] [Citation(s) in RCA: 43] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2012] [Revised: 08/18/2012] [Accepted: 08/18/2012] [Indexed: 01/04/2023] Open
Abstract
OBJECTIVE Testosterone deficiency is a common finding in men with chronic kidney disease (CKD). Testosterone is thought to play an important anabolic role in muscle synthesis, and muscle wasting is an important and deleterious characteristic of protein-energy wasting (PEW) in CKD. It is presently unknown if reduced endogenous testosterone associates with features of muscle wasting in men with CKD. METHODS This was a cross-sectional observational study of 267 men with CKD stages 2-4 (mean ± standard deviation age 67 ± 13 years, estimated glomerular filtration rate 42.9 [interquartile range 30.2-56.7] mL/min/1.73 m²) with measurements of endogenous testosterone and surrogates of PEW such as albumin, prealbumin, high-sensitivity C-reactive protein (CRP) and normalized protein nitrogen appearance (nPNA). Fat-free mass was estimated by bioelectrical impedance vector analysis (BIVA) and muscle strength by handgrip dynamometry. RESULTS Across decreasing thirds of testosterone distribution, patients were incrementally older and CRP levels rose significantly. Prealbumin, hemoglobin, nPNA, handgrip strength, and BIVA estimated surrogates of muscle mass and nutritional status (fat-free mass, body cell mass, and phase angle) were progressively reduced (P < .05 for all). In multivariate regression analyses including age, renal function, and other important confounders, testosterone significantly and independently contributed to explain the variances of handgrip strength and fat-free mass (P < .05 for all). CONCLUSIONS Endogenous testosterone independently associates with muscle strength and fat-free mass in men with moderate CKD. It is plausible that the reduction in testosterone levels that accompanies CKD may further contribute to the procatabolic environment leading to muscle wasting.
Collapse
|
52
|
Barril G, Anaya S, Vozmediano C, Celayeta AO, Novillo R, Garcia-Bernal V, Beired I, Huarte E, Chacón JC, Martín J, Santana H, Grande J, Chacon JC, Garcia M, Sousa F, J Gago M, Sánchez R, López-Montes A, de Gracia R, Tornero F, Usón J, Pousa M, Cigarran S, Giorgi M, Rdez Cubillo B, Herrero J, Izdo MJ, Abaigar P. SPANISH MULTICENTRIC STUDY ABOUT NUTRITION-INFLAMATIONhn WITH MID DILUTION (ENIMID STUDY): PRELIMINARY RESULTS. Kidney Res Clin Pract 2012. [DOI: 10.1016/j.krcp.2012.04.338] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
53
|
Usvyat LA, Raimann J, Thijssen S, van der Sande FM, Kooman J, Levin NW, Kotanko P, Von Gersdorff G, Schaller M, Bayh I, Etter M, Grassmann A, Guinsburg A, Kooman J, Lam M, Marcelli D, Marelli C, Scatizzi L, Tashman A, Thijssen S, Toffelmire T, Usvyat L, Van der Sande F, Wang Y, Levin NW, Barth C, Kotanko P, Moffitt T, Moffitt T, Hariton F, Devlin M, Garrett P, Hannon-Fletcher M, Ekramzadeh M, Sohrabi Z, Salehi M, Fallahzadeh MK, Ayatollahi M, Geramizadeh B, Hassanzadeh J, Sagheb MM, Beberashvili I, Beberashvili I, Sinuani I, Azar A, Kadoshi H, Shapiro G, Feldman L, Averbukh Z, Weissgarten J, Abe Y, Watanabe M, Ito K, Sasatomi Y, Ogahara S, Nakashima H, Saito T, Witt S, Kunze R, Guth HJ, Skarabis H, Kunze R, Vienken J, Nowak P, Wilk R, Mamelka B, Prymont-Przyminska A, Zwolinska A, Sarniak A, Wlodarczyk A, Rysz J, Nowak D, Trajceska L, Dzekova-Vidimliski P, Gelev S, Arsov S, Sikole A, Sonikian M, Dona A, Skarakis I, Metaxaki P, Chiotis C, Papoutsis I, Karaitianou A, Spiliopoulou C, Marcelli D, Tashman A, Guinsburg A, Grassmann A, Barth C, Marelli C, Van der Sande FM, Von Gersdorff G, Bayh I, Kooman J, Scatizzi L, Lam M, Schaller M, Etter M, Thijssen S, Toffelmire T, Wang Y, Usvyat LA, Kotanko P, Levin NW, Teta D, Teta D, Tappy L, Theumann N, Halabi G, Gauthier T, Mathieu C, Tremblay S, Coti P, Burnier M, Zanchi A, Martinez Vea A, Cabre C, Villa D, Munoz M, Vives JP, Arruche M, Soler J, Compte MT, Aguilera J, Romeu M, Giralt M, Barril G, Anaya S, Vozmediano C, Celayeta A, Novillo R, Bernal V, Beiret I, Huarte E, Martin J, Santana H, Torres G, Sousa F, Sanchez R, Lopez-Montes A, Tornero F, Uson J, Pousa M, Giorgi M, Rdez Cubillo B, Malhotra R, Malhotra R, Usvyat L, Abbas SR, Thjissen S, Carter M, Etter M, Tashman A, Guinsburg A, Grassmann A, Barth C, Marelli C, Van der Sande F, von Gersdorff G, Bayh I, Kooman J, Scatizzi L, Lam M, Schaller M, Toffelmire T, Wang Y, Marcelli D, Levin N, Kotanko P, Jens R, Tepel M, Katharina E, Andrea H, Simone F, Florian S, Slusanschi O, Garneata L, Moraru R, Preoteasa E, Barbulescu C, Santimbrean C, Klein C, Dragomir D, Mircescu G, Idorn T, Knop F, Holst JJ, Hornum M, Feldt-Rasmussen B, Son YK, An WS, Kim SE, Kim KH, Garneata L, Slusanschi O, Preoteasa E, Barbulescu C, Santimbrean C, Klein C, Mircescu G, Borrelli S, Minutolo R, De Nicola L, Conte G, De Simone W, Zito B, Guastaferro P, Nigro F, Bassi A, Leone L, Credendino O, Genualdo R, Capuano M, Iulianiello G, Auricchio MR, Sezer S, Bal Z, Tutal E, Erkmen Uyar M, Ozdemir Acar FN, Ribeiro S, Faria MS, Melo F, Sereno J, Freitas I, Mendonca M, Nascimento H, Fernandes J, Rocha-Pereira P, Miranda V, Mendonca D, Quintanilha A, Belo L, Costa E, Reis F, Santos-Silva A, Valtuille R, Casos ME, Fernandez EA. Nutrition, inflammation and oxidative stress - CKD 5D. Nephrol Dial Transplant 2012. [DOI: 10.1093/ndt/gfs228] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
54
|
Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Long-term virological follow up of patients with occult hepatitis C virus infection. Liver Int 2011; 31:1519-24. [PMID: 22093326 DOI: 10.1111/j.1478-3231.2011.02613.x] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/14/2011] [Accepted: 07/03/2011] [Indexed: 12/26/2022]
Abstract
BACKGROUND Patients with occult hepatitis C virus (HCV) infection (HCV-RNA in liver without detectable anti-HCV and serum HCV-RNA) may have viral RNA in peripheral blood mononuclear cells (PBMCs) and in serum after ultracentrifugation, and may present HCV-specific T-cell responses, but it is unknown whether these markers persist to be detectable over time. AIM To perform a prospective virological long-term follow up of patients with occult HCV. METHODS Viral markers were tested every 3-4 months during 55.7 ± 20.3 months in 37 patients with occult HCV who were under ursodeoxycholic acid treatment. RESULTS Viral RNA was detectable in PBMCs of 31 patients during the follow up. In 23 of them, viral RNA in PBMCs was detected intermittently and in the other eight patients HCV-RNA was positive in a single sample. After ultracentrifugation, serum HCV-RNA was detected in 33 patients, being the viraemia intermittently detectable in 28, whereas in the remaining five patients, serum HCV-RNA was positive only once. Only one patient tested always HCV-RNA negative in PBMCs and in ultracentrifuged serum during follow up. Specific Core, NS3, and/or NS4 T-cell responses were found in 31 of the patients. The patient who was always HCV-RNA negative in PBMCs and in ultracentrifuged serum had specific HCV-T-cell responses. CONCLUSIONS Occult HCV infection persists over time with fluctuating viraemia levels that induce and maintain specific T-cell responses against viral proteins.
Collapse
|
55
|
Grzegorzewska AE, Wobszal P, Jagodzinski PP, Barril G, Quiroga JA, Arenas D, Cigarran S, Herrero J, Caro P, Garcia N, Alcazar JM, Martinez P, Martin Gomez MA, Gonzalez Parra E, Castillo I, Bartolome J, Carreno V, Fukuma S, Akizawa T, Saito A, Akiba T, Kurokawa K, Fukuhara S, Sens F, Labeeuw M, Schott-Pethelaz AM, Colin C, Villar E, Wabel P, Chazot C, Wieskotten S, Moissl U, Chamney P, Wizemann V, Raimann JG, Liu L, Abbas S, Zhu F, Kaysen GA, Kotanko P, Levin NW. Dialysis / Complications. Clin Kidney J 2011. [DOI: 10.1093/ndtplus/4.s2.17] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
56
|
Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol 2010; 82:1554-9. [PMID: 20648609 DOI: 10.1002/jmv.21866] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Abstract
The diagnosis of occult hepatitis C virus (HCV) infection is based on the presence of HCV-RNA in the liver. This study aimed to evaluate the use of combining non-invasive assays to diagnose occult HCV. A total of 122 patients with occult HCV (HCV-RNA in the liver without detectable anti-HCV and serum HCV-RNA) and 45 patients with cryptogenic chronic hepatitis (without HCV-RNA in the liver and negative for anti-HCV and serum HCV-RNA) were included. HCV-RNA was tested in peripheral blood mononuclear cells (PBMCs) and in 2 ml of ultracentrifuged serum. Anti-core HCV was examined by a non-commercial enzyme-linked immunosorbent assay. All controls were negative for the three HCV markers studied. Among patients with occult HCV, 36% were anti-core HCV positive, 57% had serum HCV-RNA after ultracentrifugation, and 61% had HCV-RNA in PBMCs. Combining the results of the assays, 91% of the patients were positive for at least one marker. Intrahepatic HCV-RNA load was significantly higher in patients who were positive simultaneously for the three HCV markers than in patients who were negative for all markers (P = 0.006) and than in those with one or two HCV markers (P = 0.039). Replication of HCV in liver was detected more frequently in patients with three (93%, P = 0.002), two (82%, P = 0.001), and one HCV marker (73%, P = 0.011) than in those without markers (27%). In conclusion, testing for all these markers allows diagnosis of occult HCV without the need for a liver biopsy and these assays may help to elucidate the clinical significance of occult HCV infection.
Collapse
|
57
|
Barril G, Bartolomé J, Sanz P, Buoncristiani E, Traver JA, Selgas R, Buoncristiani U, Castillo I, Quiroga JA, Carreño V. Effect of hemodialysis schedules and membranes on hepatocyte growth factor and hepatitis C virus RNA levels. J Med Virol 2010; 82:763-7. [PMID: 20336716 DOI: 10.1002/jmv.21469] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Hemodialysis induces production of the hepatocyte growth factor (HGF) and decrease of serum hepatitis C virus (HCV) RNA in patients with HCV infection, but it is not known if the hemodialysis schedule or type of membrane affect both the HGF production and HCV viremia. The effects on both parameters of alternate-day intermittent hemodialysis and short-daily hemodialysis and high and low flux membranes were investigated in 41 patients treated by hemodialysis. Sixteen (39%) patients were anti-HCV positive and 11 (69%) had HCV RNA. Twenty-six patients were on alternate-day intermittent and 15 on short-daily hemodialysis. High flux membranes were used for 29 patients and low flux membranes for 12 patients. A decrease in HCV RNA was observed at the end of hemodialysis (8.6 x 10(5) +/- 1.1 x 10(6) IU/ml vs. 4.4 x 10(5) +/- 7.3 x 10(5) IU/ml, P = 0.003). The proportion of HCV RNA decrease was similar in patients dialyzed with both schedules and with both types of membranes. The HGF levels increased from 2,605.9 +/- 1,428.7 to >8,000 pg/ml at 15 min. At the end of the session, the HGF levels decreased to 5,106.7 +/- 2,533.9 pg/ml. The HGF levels at the start of the next session were similar to those at baseline (2,680.0 +/- 1,209.3 pg/ml). The increase and dynamics of the HGF levels were similar in patient's hemodialyzed with both schedules and with both types of membranes. These results suggest that changes in HCV RNA and HGF levels during hemodialysis are not influenced by the schedule or type of membrane used.
Collapse
|
58
|
García de Lorenzo A, Arrieta J, Ayúcar A, Barril G, Huarte E. [Intra-dialysis parenteral nutrition in chronic renal patients: consensus SEN-SENPE]. NUTR HOSP 2010; 25:375-377. [PMID: 20593117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2010] [Accepted: 03/16/2010] [Indexed: 05/29/2023] Open
Abstract
Given the high prevalence of the hyponutrition state among haemodialysis patients and knowing that this implies an increase in the rates of infection, hospitalisation and hospital stay, which translates into an increase in global morbid-mortality, the Spanish Society of Nephrology (SEN) and the Spanish Society of Parenteral and Enteral Nutrition (SENPE) have reached a consensus on the indications, contraindications, and limitations of Intra-Dialysis Parenteral Nutrition (IDPN.) This consensus considers IDPN as a valid alternative to other types of nutritional support when these show their lack of efficacy. The bases are set regarding the timing of nutritional intervention with IDPN, its ideal composition, the time of administration, its controls, follow-up schedules, and the time at which the nutritional support has to be discontinued.
Collapse
|
59
|
Domingo P, Knobel H, Gutiérrez F, Barril G, Fulladosa X. Evaluación y tratamiento de la nefropatía en el paciente con infección por VIH-1. Una revisión práctica. Enferm Infecc Microbiol Clin 2010; 28:185-98. [DOI: 10.1016/j.eimc.2009.05.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2008] [Revised: 04/29/2009] [Accepted: 05/12/2009] [Indexed: 01/11/2023]
|
60
|
Barril G, Castillo I, Carreño V. Evidence of Occult Hepatitis C Virus Infection in Hemodialysis Patients. Am J Kidney Dis 2009; 54:980-1; author reply 981. [DOI: 10.1053/j.ajkd.2009.07.028] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2009] [Accepted: 07/24/2009] [Indexed: 11/11/2022]
|
61
|
Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Presence of HCV-RNA after ultracentrifugation of serum samples during the follow-up of chronic hepatitis C patients with a sustained virological response may predict reactivation of hepatitis C virus infection. Aliment Pharmacol Ther 2009; 30:477-86. [PMID: 19523175 DOI: 10.1111/j.1365-2036.2009.04066.x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
BACKGROUND Concentration of viral particles by ultracentrifugation of serum prior to PCR allows detection of hepatitis C virus (HCV) RNA in patients with undetectable viral RNA by conventional PCR assays. AIM To analyse if HCV-RNA is detected after serum ultracentrifugation in chronic hepatitis C patients with a sustained virological response to antiviral therapy (defined as serum HCV-RNA negativity by conventional assays 6 months after the end of therapy). METHODS HCV-RNA was tested using real-time PCR in ultracentrifuged sera collected during the post-treatment follow-up (mean: 42 +/- 27 months) in 57 sustained virological responders (SVR). RESULTS After serum ultracentrifugation, HCV-RNA was detected on at least one occasion during the follow-up in 29/57 (51%) SVR. Thirteen (23%) of these 57 SVR suffered a reactivation 18 +/- 8 months after the end of therapy (reappearance of serum HCV-RNA detectable by conventional assays). Among reactivated patients, 11/13 (85%) had HCV-RNA in ultracentrifuged serum samples (detectable 10 +/- 5 months before reactivation), while HCV-RNA was positive after ultracentrifugation in 18/44 (41%) long-term SVR (P = 0.01). Persistence of detectable HCV-RNA after serum ultracentrifugation was associated with reactivation (P = 0.001). CONCLUSIONS Serum ultracentrifugation prior to PCR allows detection of HCV-RNA in SVR and its persistence may predict late reactivation.
Collapse
|
62
|
Castillo I, Bartolomé J, Quiroga JA, Barril G, Carreño V. Hepatitis C virus infection in the family setting of patients with occult hepatitis C. J Med Virol 2009; 81:1198-203. [PMID: 19475603 DOI: 10.1002/jmv.21483] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Abstract
Family members of patients with chronic hepatitis C virus (HCV) infection are at increased risk of HCV infection but the prevalence of HCV among family members of patients with occult HCV infection is not known. Anti-HCV, serum HCV RNA and levels of liver enzymes were determined in 102 family members of 50 index patients with occult HCV infection and in 118 family members of 59 chronic hepatitis C index patients. HCV RNA and/or anti-HCV were detected in 10/102 (9.8%) relatives of patients with occult HCV infection and in 4/118 (3.4%) of patients with chronic hepatitis C. Fourteen additional family members (seven were relatives of index patients with occult HCV infection) had abnormal values of liver enzymes without serological markers of HCV infection. Two of these patients (who were relatives of two index patients with occult HCV infection) underwent a liver biopsy and were diagnosed with an occult HCV infection because HCV RNA was detected in the liver cells in the absence of serological HCV markers. In conclusion, the prevalence of HCV infection among family members of patients with occult HCV infection was similar to that found among family members of patients with chronic hepatitis C. This stresses the need to adopt strategies to prevent the transmission of HCV in the family setting of patients with occult HCV infection.
Collapse
|
63
|
Puñal Rioboó J, Sánchez-Iriso E, Ruano-Ravina A, Varela Lema ML, Sánchez-Guisande D, González-Rodríguez L, Herrero JA, Barril G, Maduell F, Hernández J, Otero A, Bajo MA, Sánchez R. Short daily versus conventional hemodialysis quality of life: a cross-sectional multicentric study in Spain. Blood Purif 2009; 28:159-64. [PMID: 19590183 DOI: 10.1159/000227784] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2008] [Accepted: 02/19/2009] [Indexed: 11/19/2022]
Abstract
BACKGROUND End-stage renal disease is a major health problem worldwide nowadays. Although conventional hemodialysis is the most widely used modality, short daily hemodialysis has been proposed as a more physiologic treatment. The objective of this article is to compare the quality of life of patients on each hemodialysis modality. METHODS A multicentric cross-sectional study was performed in 9 Spanish hospitals. Patients treated for at least 3 months with conventional or short daily hemodialysis were included and quality of life measured using the Euroqol-5D quality of life questionnaire. Bayesian models were used for analyzing quality of life results. RESULTS Ninety-three patients were included, 27 were on daily hemodialysis and 66 on conventional hemodialysis. All models demonstrated a better quality of life for daily hemodialysis versus conventional hemodialysis. Only 14% of the patients on conventional hemodialysis were willing to change to a daily schedule. CONCLUSIONS Short daily hemodialysis shows a better quality of life than conventional hemodialysis with all Bayesian approaches considered.
Collapse
|
64
|
Quiroga JA, Castillo I, Llorente S, Bartolomé J, Barril G, Carreño V. Identification of serologically silent occult hepatitis C virus infection by detecting immunoglobulin G antibody to a dominant HCV core peptide epitope. J Hepatol 2009; 50:256-63. [PMID: 19070391 DOI: 10.1016/j.jhep.2008.08.021] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2008] [Revised: 07/28/2008] [Accepted: 08/25/2008] [Indexed: 12/14/2022]
Abstract
BACKGROUND/AIMS Occult HCV infection has been described among anti-HCV-HCV RNA-negative individuals with abnormal transaminase values in whom HCV RNA is detected in liver. METHODS IgG antibody to an HCVcore-derived peptide (anti-HCVcore) was investigated in 145 patients with serologically silent occult HCV infection. RESULTS At the time of the diagnostic biopsy 45/145 (31%) occult HCV-infected patients tested IgG anti-HCVcore-positive but none of the 140 patients with HCV-unrelated liver disease (P<0.001). Among 23 IgG anti-HCVcore-positive patients at baseline, 22 remained antibody-reactive (one became antibody-negative). Similarly, 17/31 baseline anti-HCVcore-negative patients remained non-reactive whereas 14 seroconverted to IgG anti-HCVcore (although transiently in 10 patients). Thus, a total of 59/145 (40.7%) patients with occult HCV infection showed IgG anti-HCVcore reactivity at any time point analyzed, including 14 initially non-reactive patients. By supplemental immunoblot assay 16 sera reacted weakly with an HCVcore-peptide band (indeterminate result) of which 10 (62.5%) reacted in the IgG anti-HCVcore assay. Occult HCV-infected patients who tested anti-HCVcore-positive showed more frequently signs of necro-inflammation (P=0.035) and greater percentages of HCV RNA-positive hepatocytes (P=0.004) compared with those anti-HCVcore-negative. CONCLUSIONS This work documents that IgG anti-HCVcore testing identifies occult HCV infection among seronegative, non-viremic patients using screening tests and may be useful in tracking anti-HCV-negative infections.
Collapse
|
65
|
Trullàs JC, Barril G, Cofan F, Moreno A, Cases A, Fernandez-Lucas M, Martinez-Ara J, Ceballos M, Garcia-de-Diego J, Muñiz ML, Molina J, Martínez-Castelao A, González-Garcia J, Miró JM. Prevalence and clinical characteristics of HIV type 1-infected patients receiving dialysis in Spain: results of a Spanish survey in 2006: GESIDA 48/05 study. AIDS Res Hum Retroviruses 2008; 24:1229-35. [PMID: 18834322 DOI: 10.1089/aid.2008.0158] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
End-stage renal diseases (ESRD) are becoming more frequent in HIV-infected patients. In Europe there is little information about HIV-infected patients on dialysis. A cross-sectional multicenter survey in 328 Spanish dialysis units was conducted in 2006. Information from 14,876 patients in dialysis was obtained (81.6% of the Spanish dialysis population). Eighty-one were HIV infected (0.54%; 95% CI, 0.43-0.67), 60 were on hemodialysis, and 21 were on peritoneal dialysis. The mean (range) age was 45 (28-73) years. Seventy-two percent were men and 33% were former drug users. The mean (range) time of HIV infection was 11 (1-27) years and time on dialysis was 4.6 (0.4-25) years. ESRD was due to glomerulonephritis (36%) and diabetes (15%). HIV-associated nephropathy was not reported. Eighty-five percent were on HAART, 76.5% had a CD4 T cell count above 200 cells, and 73% had undetectable viral load. Thirty-nine percent of patients met criteria for inclusion on the renal transplant (RT) waiting list but only 12% were included. Sixty-one percent had HCV coinfection. HCV-coinfected patients had a longer history of HIV, more previous AIDS events, parenteral transmission as the most common risk factor for acquiring HIV infection, and less access to the RT waiting list (p < 0.05). The prevalence of HIV infection in Spanish dialysis units in 2006 was 0.54% HCV coinfection was very frequent (61%) and the percentage of patients included on the Spanish RT waiting list was low (12%).
Collapse
|
66
|
Barril G, Castillo I, Arenas MD, Espinosa M, Garcia-Valdecasas J, Garcia-Fernández N, González-Parra E, Alcazar JM, Sánchez C, Diez-Baylón JC, Martinez P, Bartolomé J, Carreño V. Occult hepatitis C virus infection among hemodialysis patients. J Am Soc Nephrol 2008; 19:2288-92. [PMID: 18684893 DOI: 10.1681/asn.2008030293] [Citation(s) in RCA: 85] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022] Open
Abstract
Occult hepatitis C virus (HCV) infection (i.e., detectable HCV-RNA in the liver or peripheral blood mononuclear cells) in the absence of both serum HCV-RNA and anti-HCV antibodies has not been investigated in hemodialysis patients. In this study, real-time PCR and in situ hybridization was used to test for the presence of genomic and antigenomic HCV-RNA in peripheral blood mononuclear cells of 109 hemodialysis patients with abnormal levels of liver enzymes. Occult HCV infection, determined by the presence of genomic HCV-RNA, was found in 45% of the patients; 53% of these patients had ongoing HCV replication, indicated by the presence of antigenomic HCV-RNA. Patients with occult HCV infection had spent a significantly longer time on hemodialysis and had significantly higher mean alanine aminotransferase levels during the 6 mo before study entry. Logistic regression analysis revealed that mortality was associated with age >60 yr (odds ratio 3.30; 95% confidence interval 1.05 to 10.33) and the presence of occult HCV infection (odds ratio 3.84; 95% confidence interval 1.29 to 11.43). In conclusion, the prevalence of occult HCV infection is high among hemodialysis patients with persistently abnormal values of liver enzymes of unknown cause. The clinical significance of occult HCV infection in these patients requires further study.
Collapse
|
67
|
Alcázar JM, Arenas MD, Alvarez-Ude F, Virto R, Rubio E, Maduell F, Fernández-Crespo P, Angoso de Guzmán M, Delgado R, Santamaría C, Alonso MA, Anaya S, Bordils A, Antolín A, González-Parra E, Pérez I, Molina Ordás A, Fernández M, Molina P, Sánchez P, Barbosa F, Palomares Solla L, Lacueva J, Barril G, Pastor JM, Gámez Matías C, Hernández PM, Nicolás MF, Ríos F. [Preliminary results of the Spanish Society of Nephrology multicenter study of quality performance measures: hemodialysis outcomes can be improved]. Nefrologia 2008; 28:597-606. [PMID: 19016632] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
INTRODUCTION The Spanish Society of Nephrology "Quality in Nephrology Working Group" (QNWG) was created in 2002. The aims of this group are the identification, diffusion, implementation and consolidation of a systematic, objective and comprehensive set of quality performance measures (QPMs) to help along the improvement of patient care and outcomes on hemodialysis, by means of strategies of feedback and benchmarking, and the design of quality improvement projects. The objective of this study is to present the preliminary results of a set of quality performance measures obtained in a group of Spanish hemodialysis centers, as well as to evaluate the repercussion of the application of the aforementioned thecniques on the observed results. METHODS During 2007 a total of 28 hemodialysis units participated in the study; 2516 patients were evaluated. A specific software was designed and used to facilitate the calculation of CPMs in each unit. The clinical indicators used refered to dialysis adequacy; anemia; mineral metabolisme; nutrition; viral infections; vascular access; mortality, morbidity (number and days of hospital admissions); and renal transplant. Every three months each center received its own data and its comparison with the rest of the group. RESULTS Except for hemoglobin levels we observed a global improvement. The percentage of centers reaching the stablished standards defined by the QNWG passed from 65% to 90,9% for Kt/V Daugirdas II (> 1,3 in > that 80% of the patients); from 71,4 % to 77,2 % for PTH (> 30 % of patients with serum PTH between 150 and 300 pg/ml); and from 42,8 % to 63,5 % for phosphate (> 75 % of patients with a serum phsphate < 5,5 mg/dl). More than 50% of centers showed an improvement in their final results as compared with their own initial results in all analyzed CPMs. Those centers that did not obtained an improvement in their results started the study with better percentages of acomplishment than those that showed a significant improvement in QPMs. (80,6+/-15,4 versus 71,8+/-16,6 respectively; p<0,001) CONCLUSIONS We are starting to make progresses in our knowledge of clinical results in our hemodialysis units, although there is still a long way to go over. To monitor and share CPMs results within hemodialysis centers might help to improve their results as well as to reduce intecenters variability.
Collapse
|
68
|
Bover J, Górriz JL, Martín de Francisco AL, Caravaca F, Barril G, Molinero LM. [Unawareness of the K/DOQI guidelines for bone and mineral metabolism in predialysis chronic kidney disease: results of the OSERCE Spanish multicenter-study survey]. Nefrologia 2008; 28:637-643. [PMID: 19016638] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
Since its publication in 2003, the K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease (CKD) have become a worldwide reference. The aim of this study was to analyze the observance to these guidelines in patients with a glomerular filtration rate < 60 ml/min/1,73m2 not yet included in dialysis in a Spanish multicenter cohort. A questionnaire by investigator/centre was completed by 32 different nephrologists participating in the OSERCE study and representing the overall Spanish public health net. We observed that biochemical parameters were measured less frequently than recommended, except in CKD stage 3. The therapeutic goals for intact PTH were not properly reported by 59 % of the consulted nephrologists for stages 3 and 4, whereas only 22% did not report them properly for stage 5. The goals for phosphorus were not adequately reported in 50 % of cases (stages 3 y 4) and 60 % (stage 5). For calcium, these values were 70 %, 73.3 % and 65.5 % for stages 3, 4 and 5, respectively. A corrected plasma calcium between 9.5 and 10.2 mg/dl is still considered adequate for 31%. As much as 87% nephrologists stated that they did not sistematically measure calcidiol plasma levels. In general, these results demonstrate that there is a great degree of unawareness of K/DOQITM predialysis guidelines. Thus, their poor implementation is probably not only due to the lower availability of approved therapeutic agents, the difficult achievement of goals or the disbelief on current recommendations. It would be desirable that forthcoming guidelines such as the KDIGO could also consider the need of educational efforts for CKD-Mineral and Bone Disorder.
Collapse
|
69
|
Barril G, Teruel JL. [Vaccination scheme in advanced chronic kidney disease]. Nefrologia 2008; 28 Suppl 3:95-99. [PMID: 19018745] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/27/2023] Open
Abstract
1. VACCINATION AGAINST HEPATITIS B a) All patients with chronic advanced renal disease and negative serology for HBsAg and antiHBs are to be vaccinated against hepatitis B (Evidence level: B). b) For classic vaccines (Engerix B and HBVAxpro) the adult vaccine dose is 40 mcg (20 mcg in the paediatric population). There are two dose regimens based on the medicinal product used: 0, 1 and 6 months with HBVAxpro and 0, 1, 2 and 6 months with Engerix B. With the new vaccine Fendrix, the dose is 20 mcg and the schedule 0, 1, 2 and 6 months (Evidence level: C). c) The antiHBs titre is to be measured 1-2 months after administration of the last dose. In patients whose antibody titres are below 10 mIU/mL, a booster may be administered, checking the response or administering a second full vaccination (Evidence level: B). d) In responders, antibody levels are to be tested at least once a year. If the antiHBs titre is below 10 mIU/mL, a booster is to be administered (Evidence level: C). 2. VACCINATION AGAINST INFLUENZA a) All patients with chronic advanced renal disease are to be vaccinated every year against influenza (Evidence level: B). b) The vaccination dose and regimen are the same as recommended for the general population (Evidence level: C) 3. VACCINATION AGAINST PNEUMOCOCCUS a) Vaccination against pneumococcus is recommended in patients with chronic renal disease associated with nephrotic syndrome or who may be future candidates for renal transplant (Evidence level: B). b) There is no evidence of the clinical value of the pneumococcal vaccine in adult patients with chronic renal failure, not transplanted. However, some regions are recommending routine vaccination in the population aged >or= 60 years, the age of a high percentage of our patients. c) To maintain immunisation, revaccination is required every 3- 5 years. 4. OTHER VACCINES a) Vaccination against hepatitis A is recommended in patients with renal failure associated with chronic liver disease or who are candidates for renal transplant (Evidence level: C). b) The recommendations for vaccination against tetanus and diphtheria are the same as for the general population (Evidence level: C). c) Chickenpox vaccine is indicated in children with chronic renal disease, particularly if they are candidates for transplant (Evidence level: B). Although there is no evidence of the value of this vaccine in adults, it is advisable to perform it in those who may be candidates for renal transplant with no protecting antibodies. d) There is no evidence of the clinical value of the vaccine against Staphylococcus aureus.
Collapse
|
70
|
Barril G, Cigarran S, Friera A, Gallego C, Fernandez Perpen A, Cirugeda A, Selgas R. Catheter malfunction due to spontaneous permcath displacement into medium suprahepatic vein. J Vasc Access 2007; 1:70-2. [PMID: 17638228 DOI: 10.1177/112972980000100208] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
One of the last options, when the other possibilities of vascular access present malfunction, is the insertion of a permanent catheter in a central vein, preferentially internal jugular vein. This option is considered when arteriovenous access is impossible. We report a case of malfunction due to a permanent catheter dis-placement solved by vascular interventional radiology.
Collapse
|
71
|
Espinosa M, Arenas MD, Aumente MD, Barril G, Buades JM, Aviles B, Carretero D, Alvarez-Lara MA, Carnicer F, Martin-Malo A, Aljama P. Anemia associated with pegylated interferon-?2a and ?2b therapy in hemodialysis patients. Clin Nephrol 2007; 67:366-73. [PMID: 17598372 DOI: 10.5414/cnp67366] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
AIMS Anemia is a well-known side effect of interferon therapy since interferons are potent inhibitors of erythropoiesis. The aim of this study was to compare the anemia associated with pegylated interferon (PEG-IFN) (alpha2a versus alpha2b therapy in hemodialysis patients (HD) with chronic hepatitis C. METHODS In order to study the anemia, doses of erythropoietic growth factors (EGF), hemoglobin (Hb) and erythropoietin resistance index (ERI) were compared at baseline and after PEG-IFN-alpha2a or alpha2b therapy in 16 HD patients with chronic C hepatitis. Pharmacokinetic studies were performed in 4 of those treated with PEG-IFN-alpha2b and 2 patients treated with PEG-IFN-alpha2a. Secondary end-points were viral response and serious adverse events. RESULTS At 4-6 months after the beginning of therapy, both PEG-IFN-alpha induced a significant increment in the erythropoietin resistance index. This increment was significantly higher in patients treated with PEG-IFN-alpha2a when compared with alpha2b (45 vs 9.9, p = 0.012). The pharmacokinetics of PEG-IFN-alpha2a and alpha2b in HD patients were different, the C(max), C(min) and the area under the serum concentration time curve, were all higher in patients treated with PEG-IFN-alpha2a compared with PEG-INF-alpha2b. Discontinuation of therapy occurred in 2 (28.5%) of the 7 patients in the PEG-IFN-alpha2a group and in 4 (44%) of the 9 patients in the PEG-IFN-alpha2b group. Three (42%) subjects in the alpha2a group and 5 (55%) in the alpha2b group had a response at the end of the 48 weeks of therapy. In 4 (44.4%) of the 9 patients treated with alpha2b the viral response was sustained. CONCLUSIONS In summary, patients treated with PEG-IFN-alpha2a have a major inhibitory effect on erythropoiesis. This could be explained by the different pharmacokinetic properties of PEG-IFN-alpha2a and alpha2b. Further studies are needed to clarify how these findings influence the efficacy, safety and cost-effectiveness of the PEG-IFN-alpha2.
Collapse
|
72
|
Cigarran S, Barril G, Cirugeda A, Bernis C, Aguilera A, Sanz P, Herraez I, Alegre L, Selgas R. Hypoalbuminemia is Also a Marker of Fluid Excess Determined by Bioelectrical Impedance Parameters in Dialysis Patients. Ther Apher Dial 2007; 11:114-20. [PMID: 17381532 DOI: 10.1111/j.1744-9987.2007.00416.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
Hypoalbuminemia may be secondary to volume expansion conditions and an independent risk factor for cardiovascular disease. Bioelectrical impedance analysis (BIA) is an accurate, non-invasive method to measure body composition, especially the water compartments in humans. The aim of this cross-sectional study is to evaluate the relationship between serum albumin concentration (SA) and hydration state measured by whole BIA. The study investigated 108 non-selected patients (73 on hemodialysis, 35 on peritoneal dialysis) with a mean age of 61.4 +/- 15.6 years, 42.7% of whom were female. The patients were allotted to groups according to their SA: Group 1, < or = 3.5 g/dL; Group 2, 3.6-4.0 g/dL; and Group 3, >4.0 g/dL. The BIA parameters used included: total body water, intracellular water (ICW), extracellular water (ECW), phase angle (PA), body cell mass (BCM), ICW/ECW ratio and ICW/ECW ratio patients/controls (fluid index). Seventy-five healthy volunteers formed the control group. A strong positive correlation was found between the PA and fluid index (r (2) = 0.993, P < 0.001), as well as between the PA and SA (r = 0.386, P < 0.001), and the ICW/ECW ratio and SA (r = 0.227, P < 0.001). The ECW was negatively correlated with SA (r = -0.330, P < 0.001). Every 0.1 g/dL decrease in SA was associated with a 0.33 L increase in ECW. Group 1 patients had lower reactance (P = 0.006), PA (P < 0.001), BCM (P = 0.012), fluid index (P < 0.001) and ICW/ECW ratio (P = 0.015), and an increased ECW (NS) than groups 2 and 3. We conclude that hypoalbuminemia is also a marker of fluid excess. The SA is associated to the fluid index and the PA allows assessment of the dry weight and its variations in an individualized manner in dialysis patients.
Collapse
|
73
|
López Revuelta K, Barril G, Caramelo C, Delgado R, García López F, García Valdecasas J, Gruss E, Jiménez Almonacid P, Martínez Castelao A, Luis Miguel J, Ortiz A, Del Pino Y Pino MD, Portolés JM, Prados C, Sanz P, Tato A, Alvarez Ude F, Angoso M, Aranaz J, Arenas MD, Lorenzo S. [Developing a Clinical Performance Measures System for hemodialysis, Quality Group, Spanish Society of Nephrology]. Nefrologia 2007; 27:542-559. [PMID: 18045030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2023] Open
|
74
|
Barril G, Sánchez Tomero JA. [Home hemodialysis: a possible and necessary alternative]. Nefrologia 2007; 27:3-5. [PMID: 17402873] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/14/2023] Open
|
75
|
Patitucci AN, Pérez MJ, Barril G, Cárcamo CM, Muñoz A. Detección de anticuerpos séricos contra Toxoplasma gondii (Nicolle y Manceaux, 1909) en llamas (Lama glama Linneaus, 1758) y alpacas (Lama pacos Linneaus, 1758 ) de Chile. ACTA ACUST UNITED AC 2006. [DOI: 10.4067/s0301-732x2006000200013] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|